A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Antroquinonol (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Golden Biotechnology Corporation
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
- 25 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.